MX2009000715A - Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. - Google Patents
Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos.Info
- Publication number
- MX2009000715A MX2009000715A MX2009000715A MX2009000715A MX2009000715A MX 2009000715 A MX2009000715 A MX 2009000715A MX 2009000715 A MX2009000715 A MX 2009000715A MX 2009000715 A MX2009000715 A MX 2009000715A MX 2009000715 A MX2009000715 A MX 2009000715A
- Authority
- MX
- Mexico
- Prior art keywords
- analogs
- derivatives
- androgen receptor
- receptor modulators
- selective androgen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
Abstract
La invención proporciona nuevos compuestos y usos de los mismos para tratar una variedad de enfermedades o condiciones en un sujeto, incluyendo, entre otras, cáncer de próstata, enfermedades y/o trastornos de desgaste de músculos o enfermedades/trastornos relacionados con huesos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83188006P | 2006-07-19 | 2006-07-19 | |
US83198806P | 2006-07-19 | 2006-07-19 | |
PCT/US2007/016311 WO2008011072A2 (en) | 2006-07-19 | 2007-07-19 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009000715A true MX2009000715A (es) | 2009-07-22 |
Family
ID=38957352
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009000715A MX2009000715A (es) | 2006-07-19 | 2007-07-19 | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
MX2009000714A MX2009000714A (es) | 2006-07-19 | 2007-07-19 | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009000714A MX2009000714A (es) | 2006-07-19 | 2007-07-19 | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US8110562B2 (es) |
EP (2) | EP2040709A2 (es) |
JP (2) | JP2009543872A (es) |
KR (2) | KR20090030345A (es) |
AR (1) | AR063208A1 (es) |
AU (2) | AU2007275737A1 (es) |
BR (2) | BRPI0713198A2 (es) |
CA (2) | CA2658096A1 (es) |
EA (2) | EA200900202A1 (es) |
IL (2) | IL196534A0 (es) |
MX (2) | MX2009000715A (es) |
WO (2) | WO2008011072A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US8637706B2 (en) | 2005-11-28 | 2014-01-28 | Gtx, Inc. | Nuclear receptor binding agents |
US20070135407A1 (en) * | 2005-11-28 | 2007-06-14 | Steiner Mitchell S | Serm reduction of lipid profiles |
US7550505B2 (en) * | 2006-07-24 | 2009-06-23 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
DK2176220T3 (da) | 2007-08-07 | 2013-06-10 | Takeda Pharmaceutical | Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. |
JP2010538093A (ja) | 2007-09-07 | 2010-12-09 | バイオノボ・インコーポレーテッド | シソ科ファミリーのセイタカナミキソウのエストロゲン性抽出物およびその使用 |
AU2008329902A1 (en) | 2007-11-19 | 2009-06-04 | Bionovo, Inc. | A process of making purified extract of scutellaria barbata D. Don |
BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2009117739A1 (en) * | 2008-03-21 | 2009-09-24 | Northeastern University | Modulators of nuclear receptor co-regulatory protein binding |
ITBO20090078A1 (it) * | 2009-02-13 | 2010-08-14 | Consiglio Nazionale Ricerche | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
WO2010116342A2 (en) * | 2009-04-10 | 2010-10-14 | Consiglio Nazionale Delle Ricerche | Non-steroidal compounds for androgen receptor modulation |
ITBO20090235A1 (it) * | 2009-04-10 | 2010-10-11 | Consiglio Nazionale Ricerche | Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi |
US8450374B2 (en) * | 2009-06-29 | 2013-05-28 | University Of Delaware | Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
RU2012134351A (ru) * | 2010-01-11 | 2014-02-20 | ДЖиТиЭкс, ИНК. | Способы лечения дисфункции мейбомиевых желез |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
EP2542687A1 (en) * | 2010-03-05 | 2013-01-09 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in fabry disease |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
PL2568806T3 (pl) | 2010-05-12 | 2017-03-31 | Radius Health, Inc. | Schematy lecznicze |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
FI20105806A0 (fi) | 2010-07-15 | 2010-07-15 | Medeia Therapeutics Ltd | Uudet aryyliamidijohdannaiset, joilla on antiandrogeenisia ominaisuuksia |
WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
TW201332953A (zh) | 2012-01-13 | 2013-08-16 | Medeia Therapeutics Ltd | 具抗雄激素性質新芳醯胺衍生物 |
AR089701A1 (es) | 2012-01-13 | 2014-09-10 | Medeia Therapeutics Ltd | Derivados de arilamida que tienen propiedades antiandrogenicas |
AU2013208847B2 (en) | 2012-01-13 | 2017-08-31 | Aranda Pharma Ltd | Novel heteroarylamide derivatives having antiandrogenic properties |
WO2013163675A1 (en) | 2012-05-02 | 2013-11-07 | Pharmaxis Ltd. | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
CA2883711A1 (en) | 2012-09-07 | 2014-03-13 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
US20140274979A1 (en) * | 2013-03-13 | 2014-09-18 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
WO2015102996A1 (en) * | 2013-12-31 | 2015-07-09 | Grasso Frank J | Extremely high loading dose |
FI3122426T3 (fi) | 2014-03-28 | 2023-03-31 | Univ Duke | Rintasyövän hoitaminen käyttäen selektiivisiä estrogeenin reseptorin modulaattoreita |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
KR101597327B1 (ko) * | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
JOP20180072A1 (ar) | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
RU2689988C2 (ru) | 2015-04-21 | 2019-05-30 | Джи Ти Икс, ИНК. | Селективные лиганды-разрушители андрогенных рецепторов (sard) и способы их применения |
US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US9815776B2 (en) | 2015-04-21 | 2017-11-14 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
PL3474841T3 (pl) | 2016-06-22 | 2022-07-11 | Ellipses Pharma Ltd | Sposoby leczenia nowotworu złośliwego piersi ar+ |
US11167007B2 (en) | 2016-08-04 | 2021-11-09 | City Of Hope | FOXM1 modulators and uses thereof |
AU2018205285C9 (en) | 2017-01-05 | 2024-05-23 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCl |
WO2019025153A1 (de) | 2017-07-31 | 2019-02-07 | Bayer Cropscience Aktiengesellschaft | Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen |
US11707449B2 (en) | 2017-10-27 | 2023-07-25 | St. Jude Children's Research Hospital, Inc. | Methods and formulations for treatment of spinobulbar muscular atrophy |
US20200305429A1 (en) | 2017-11-23 | 2020-10-01 | Basf Se | Herbicidal phenylethers |
CA3080276A1 (en) | 2017-11-23 | 2019-05-31 | Basf Se | Herbicidal pyridylethers |
CA3104395A1 (en) | 2018-07-04 | 2020-01-09 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
WO2023011596A1 (zh) * | 2021-08-05 | 2023-02-09 | 中国药科大学 | 酰胺类化合物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2684965A (en) | 1950-08-10 | 1954-07-27 | Abbott Lab | Aminoalkylpiperidines |
GB798410A (en) | 1956-01-18 | 1958-07-23 | Bofors Ab | N-alkyl-tetrahydroquinaldinic acid amides |
US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
ITMI20012060A1 (it) | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
-
2007
- 2007-07-19 AU AU2007275737A patent/AU2007275737A1/en not_active Abandoned
- 2007-07-19 MX MX2009000715A patent/MX2009000715A/es not_active Application Discontinuation
- 2007-07-19 WO PCT/US2007/016311 patent/WO2008011072A2/en active Application Filing
- 2007-07-19 KR KR1020097003232A patent/KR20090030345A/ko not_active Application Discontinuation
- 2007-07-19 BR BRPI0713198-4A patent/BRPI0713198A2/pt not_active Application Discontinuation
- 2007-07-19 WO PCT/US2007/016312 patent/WO2008011073A2/en active Application Filing
- 2007-07-19 CA CA002658096A patent/CA2658096A1/en not_active Abandoned
- 2007-07-19 KR KR1020097003234A patent/KR20090035707A/ko not_active Application Discontinuation
- 2007-07-19 US US11/826,987 patent/US8110562B2/en not_active Expired - Fee Related
- 2007-07-19 BR BRPI0713200-0A patent/BRPI0713200A2/pt not_active Application Discontinuation
- 2007-07-19 EA EA200900202A patent/EA200900202A1/ru unknown
- 2007-07-19 US US11/826,985 patent/US20090156614A1/en not_active Abandoned
- 2007-07-19 JP JP2009520822A patent/JP2009543872A/ja not_active Withdrawn
- 2007-07-19 EP EP07810587A patent/EP2040709A2/en not_active Withdrawn
- 2007-07-19 EA EA200900203A patent/EA200900203A1/ru unknown
- 2007-07-19 EP EP07836135A patent/EP2041077A2/en not_active Withdrawn
- 2007-07-19 AU AU2007275736A patent/AU2007275736A1/en not_active Abandoned
- 2007-07-19 CA CA002658098A patent/CA2658098A1/en not_active Abandoned
- 2007-07-19 MX MX2009000714A patent/MX2009000714A/es not_active Application Discontinuation
- 2007-07-19 JP JP2009520821A patent/JP2009543871A/ja not_active Withdrawn
- 2007-07-20 AR ARP070103235A patent/AR063208A1/es unknown
-
2009
- 2009-01-15 IL IL196534A patent/IL196534A0/en unknown
- 2009-01-15 IL IL196533A patent/IL196533A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8110562B2 (en) | 2012-02-07 |
WO2008011073A3 (en) | 2008-10-23 |
WO2008011072A2 (en) | 2008-01-24 |
AU2007275736A1 (en) | 2008-01-24 |
JP2009543872A (ja) | 2009-12-10 |
EA200900203A1 (ru) | 2009-06-30 |
WO2008011073A2 (en) | 2008-01-24 |
IL196533A0 (en) | 2009-11-18 |
KR20090035707A (ko) | 2009-04-10 |
WO2008011072A3 (en) | 2008-06-05 |
US20090156614A1 (en) | 2009-06-18 |
CA2658096A1 (en) | 2008-01-24 |
BRPI0713198A2 (pt) | 2012-10-16 |
IL196534A0 (en) | 2009-11-18 |
EP2041077A2 (en) | 2009-04-01 |
KR20090030345A (ko) | 2009-03-24 |
AU2007275737A1 (en) | 2008-01-24 |
AR063208A1 (es) | 2009-01-14 |
EA200900202A1 (ru) | 2009-06-30 |
EP2040709A2 (en) | 2009-04-01 |
US20110077221A1 (en) | 2011-03-31 |
JP2009543871A (ja) | 2009-12-10 |
BRPI0713200A2 (pt) | 2012-04-10 |
CA2658098A1 (en) | 2008-01-24 |
MX2009000714A (es) | 2009-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009000715A (es) | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. | |
MX2009000385A (es) | Acil-anilidas sustituidas y metodos de uso de las mismas. | |
MX2009001962A (es) | Acilanilidas substituidas y metodos de uso de las mismas. | |
HRP20150437T1 (en) | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | |
EA011306B8 (ru) | Избирательные модуляторы андрогеновых рецепторов и способы их применения | |
PL1979355T3 (pl) | Pochodne spiro imidazoli jako modulatory PPAR | |
BG108495A (en) | 5-ht receptor ligands and uses thereof | |
MX2009007075A (es) | Metodos de uso para analogos de ciclopamina. | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
WO2008030367A3 (en) | Selective myostatin inhibitors | |
MX2010001378A (es) | Uso terapeutico de anticuerpos del receptor anti-tweak. | |
SG146657A1 (en) | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
HK1126421A1 (zh) | 用於治療***癌及與雄性激素受體相關的疾病的雄性激素受體調質 | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
IL177483A0 (en) | Means for transdermal administration of nicotine | |
PT2229369T (pt) | Derivados de 6,7-dialcoxi-quinazolina úteis para tratamento de distúrbios relacionados com o cancro | |
MX2009009415A (es) | Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina. | |
MY146506A (en) | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor | |
GB2466912A (en) | Compositions and methods for treating lysosomal disorders | |
EP2224919A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES | |
MX2010004003A (es) | N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas. | |
EA200501761A1 (ru) | Пролекарственные формы селективных модуляторов андрогеновых рецепторов и способы их применения | |
MY158253A (en) | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor | |
TW200740766A (en) | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands | |
MX2008002158A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |